Disease specific patient-reported outcome (pro) instruments for hematologic malignancies (hm)
Само за регистроване кориснике
2019
Конференцијски прилог (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
In HM clinical trials PROs are an important complement to their clinical
endpoints and are key to understanding the overall treatment benefit and effectiveness of new interventions being tested. To guide researchers and clinicians in
their choice of PRO assessment tools, this poster will provide an overview of HM
specific PRO instruments, describe their content, and highlight commonalities and
differences between measures.
Кључне речи:
patient-reported outcome (pro) / hematologic malignancies (hm)Извор:
Value in Health, 2019, 22, S528-S528Издавач:
- Elsevier Science Inc, New York
Институција/група
Psihologija / PsychologyTY - CONF AU - Hajdukova, Brown E. AU - Medić, Nenad AU - Zupan, Zorana AU - Rudell, K. PY - 2019 UR - http://reff.f.bg.ac.rs/handle/123456789/2889 AB - In HM clinical trials PROs are an important complement to their clinical endpoints and are key to understanding the overall treatment benefit and effectiveness of new interventions being tested. To guide researchers and clinicians in their choice of PRO assessment tools, this poster will provide an overview of HM specific PRO instruments, describe their content, and highlight commonalities and differences between measures. PB - Elsevier Science Inc, New York C3 - Value in Health T1 - Disease specific patient-reported outcome (pro) instruments for hematologic malignancies (hm) EP - S528 SP - S528 VL - 22 UR - https://hdl.handle.net/21.15107/rcub_reff_2889 ER -
@conference{ author = "Hajdukova, Brown E. and Medić, Nenad and Zupan, Zorana and Rudell, K.", year = "2019", abstract = "In HM clinical trials PROs are an important complement to their clinical endpoints and are key to understanding the overall treatment benefit and effectiveness of new interventions being tested. To guide researchers and clinicians in their choice of PRO assessment tools, this poster will provide an overview of HM specific PRO instruments, describe their content, and highlight commonalities and differences between measures.", publisher = "Elsevier Science Inc, New York", journal = "Value in Health", title = "Disease specific patient-reported outcome (pro) instruments for hematologic malignancies (hm)", pages = "S528-S528", volume = "22", url = "https://hdl.handle.net/21.15107/rcub_reff_2889" }
Hajdukova, B. E., Medić, N., Zupan, Z.,& Rudell, K.. (2019). Disease specific patient-reported outcome (pro) instruments for hematologic malignancies (hm). in Value in Health Elsevier Science Inc, New York., 22, S528-S528. https://hdl.handle.net/21.15107/rcub_reff_2889
Hajdukova BE, Medić N, Zupan Z, Rudell K. Disease specific patient-reported outcome (pro) instruments for hematologic malignancies (hm). in Value in Health. 2019;22:S528-S528. https://hdl.handle.net/21.15107/rcub_reff_2889 .
Hajdukova, Brown E., Medić, Nenad, Zupan, Zorana, Rudell, K., "Disease specific patient-reported outcome (pro) instruments for hematologic malignancies (hm)" in Value in Health, 22 (2019):S528-S528, https://hdl.handle.net/21.15107/rcub_reff_2889 .